SLC5A2 and chronic kidney disease: The class reduces HF hospitalizations and improves kidney function; some SGLT2 inhibitors have been shown to reduce the risk of other cardiovascular events.115–118,121,122 Dapagliflozin and empagliflozin have been shown to improve HF and/or CKD outcomes in patients without diabetes.123,176 The cardiorenal benefits of SGLT2 inhibitors are independent of glucose lowering, and the class may be used to an eGFR <20 mL/min/1.73 m2.